Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Dec 14;13(12):e076713.
doi: 10.1136/bmjopen-2023-076713.

Effectiveness of transcranial direct current stimulation (tDCS) as adjunctive treatment for chronic headache in adults with clinically stable systemic lupus erythematosus (SHADE): a randomised double-blind multiarm sham controlled clinical trial

Affiliations
Randomized Controlled Trial

Effectiveness of transcranial direct current stimulation (tDCS) as adjunctive treatment for chronic headache in adults with clinically stable systemic lupus erythematosus (SHADE): a randomised double-blind multiarm sham controlled clinical trial

Riwanti Estiasari et al. BMJ Open. .

Abstract

Background: Chronic headache is a 'silent' neuropsychiatric systemic lupus erythematosus symptom with heterogeneous prevalence, potentially reaching 54.4%. It may reduce quality of life by increasing the likelihood of depression and sleep disturbance. While pharmacotherapy remains the first-line treatment, the current management is still challenging and needs other non-invasive modalities. An effective, tolerable and disease-specific treatment modality including transcranial direct current stimulation (tDCS) is considered to reduce the frequency of chronic headaches, including in SLE. Until recently, there was no standard protocol for tDCS in treating headaches.

Methods and analysis: SHADE is a single-centre randomised double-blind multiarm sham-controlled trial for adults with clinically stable SLE, chronic headaches and without history of traumatic brain injury, brain infection, stroke or brain tumour. Random allocation is conducted to 88 subjects into 3 treatment groups (administration at primary motor, primary sensory and dorsolateral prefrontal cortex) and control group in 1:1:1:1 ratio. The primary endpoint is reduced number of headache days after adjunctive tDCS. The secondary endpoints are reduced headache intensity, increased quality of life, increased sleep quality, decreased depression and reduced analgesics use. The outcome is measured monthly until 3-month postintervention using headache diary, 36-Item Short Form Survey, Chronic Headache Quality of Life Questionnaire, Pittsburgh Sleep Quality Index and Mini International Neuropsychiatry Interview version 10 (MINI ICD 10). Intention-to-treat analysis will be performed to determine the best tDCS electrode placement.

Ethics and dissemination: Ethical approval had been obtained from the local Institutional Review Board of Faculty of Medicine Universitas Indonesia. Results will be published through scientific relevant peer-reviewed journals.

Trial registration number: NCT05613582.

Keywords: Clinical Trial; Neurological pain; Quality of Life.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Electrode placement in the (A) M1 experimental group. (B) S1 experimental group. (C) D experimental group.

References

    1. Elolemy G, Al Rashidi A, Youssry D, et al. Headache in patients with systemic lupus erythematosus: characteristics, brain MRI patterns, and impact. Egypt Rheumatol Rehabil 2021;48:31. 10.1186/s43166-021-00078-x - DOI
    1. Vos T, Barber RM, Bell B. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet 2015;386:743–800. 10.1016/S0140-6736(15)60692-4 - DOI - PMC - PubMed
    1. Ahmed F, Parthasarathy R, Khalil M. Chronic daily headaches. Ann Indian Acad Neurol 2012;15:S40–50. 10.4103/0972-2327.100002 - DOI - PMC - PubMed
    1. Tu Y, Fu Z, Zeng F, et al. Abnormal thalamocortical network dynamics in migraine. Neurology 2019;92:e2706–16. 10.1212/WNL.0000000000007607 - DOI - PMC - PubMed
    1. Biscetti L, De Vanna G, Cresta E, et al. Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms. J Neuroinflammation 2021;18:259. 10.1186/s12974-021-02229-5 - DOI - PMC - PubMed

Publication types

Associated data